Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Buffalo, New York Clinical Trials

A listing of Buffalo, New York clinical trials actively recruiting patient volunteers.

RESULTS

Found (5) clinical trials

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

The DELIVER-MS study seeks to answer the question: Does early treatment with highly effective DMT improve the prognosis for people with MS? This is an area of significant controversy and no data currently exist to guide treatment choices for patients and clinicians. The study results will help guide overall treatment ...

Phase

0.75 miles

Learn More »

A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

The screening phase will last up to 24 weeks. In the double-blind treatment phase, participants will undergo at least 120 weeks of study treatment. Study drug (ocrelizumab or placebo) will be administered every 24 weeks. In the FU1 phase, all participants who discontinue prematurely from the double-blind treatment phase will ...

Phase

0.86 miles

Learn More »

Measurement Training and Feedback System: Family-Based Services

Discovering and disseminating effective methods to improve the quality of treatment services for adolescent substance use (ASU) within the national behavioral healthcare system is an urgent public health priority. Despite the strong legislative and policy focus on quality of care evident in the Children's Health Insurance Program Reauthorization Act of ...

Phase N/A

0.86 miles

Learn More »

Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome

This is a Phase 2, multicenter, double-blind (sponsor-unblinded), randomized, placebo-controlled study to assess the safety and efficacy of Elagolix in women with polycystic ovary syndrome (PCOS). PCOS is one of the most common hormonal disorders in women of reproductive age, yet few treatment options are available. This study will help ...

Phase

8.03 miles

Learn More »

Evaluate Eribulin ORA in Subjects With Solid Tumors

This is a multicenter, open-label safety, tolerability, pharmacokinetic, and activity study. Eligible subjects will be adults with advanced solid tumors. Groups of 3 to 6 subjects will receive a single dose of Eribulin ORA on Day 1 and Day 8 of a 21 day cycle and will be followed for ...

Phase

8.87 miles

Learn More »